Inhibition of the renin-angiotensin system during fetal kidney development.

Clin Exp Pediatr

Department of Pediatrics, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.

Published: March 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940092PMC
http://dx.doi.org/10.3345/cep.2020.01228DOI Listing

Publication Analysis

Top Keywords

inhibition renin-angiotensin
4
renin-angiotensin system
4
system fetal
4
fetal kidney
4
kidney development
4
inhibition
1
system
1
fetal
1
kidney
1
development
1

Similar Publications

Chronic kidney disease (CKD) affects almost 10% of the global population and is a significant health issue. The presence of CKD increases the risk of fatal and non-fatal cardiovascular events, overall mortality, and progression of renal damage leading to kidney failure. Inhibiting the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme inhibitor or angiotensin II receptor blockers reduces proteinuria and slows eGFR decline in CKD patients.

View Article and Find Full Text PDF

Background: To investigate the role of self-peripheral blood mesenchymal stem cell (PBMSC)-derived exosomes (Exos) in enhancing renal sympathetic denervation (RD)-mediated heart regeneration following myocardial infarction (MI) in a porcine model.

Methods: Pigs (ejection fraction [EF] < 40% post-MI) were randomised to early sham RD or RD. At 2 weeks post-MI, autologous PBMSC-Exos were collected.

View Article and Find Full Text PDF

Background: Glucagon-like peptide-1 (GLP-1) shows promise for treating hyperoxia-induced bronchopulmonary dysplasia (BPD), but its mechanisms remain unclear. This study investigated the effects and potential mechanisms of GLP-1 using a hyperoxia-induced neonatal BPD mouse model.

Methods: Sprague-Dawley (SD) newborn rats were randomly assigned to four groups: control, hyperoxia, hyperoxia+Liraglutide, and hyperoxia+Liraglutide+A779.

View Article and Find Full Text PDF

Individual responses to exercise training vary widely, shaping athletic performance, rehabilitation outcomes and long‑term health trajectories. This review synthesizes evidence on how angiotensin-converting enzyme (ACE) activity, influenced by genetic variation, epigenetic regulation and pharmacological modulation, shapes adaptations in skeletal muscle hypertrophy, cardiac remodelling, erythropoiesis, endurance capacity and injury susceptibility. We highlight ACE's nuanced role, showing that pharmacological inhibition selectively attenuates cardiac and haematological adaptations, such as haemoglobin mass and lean body mass, without affecting peripheral muscle adaptations and aerobic performance.

View Article and Find Full Text PDF

Compared to bortezomib treatment, multiple myeloma (MM) treatment with the proteasome inhibitor carfilzomib is associated with a higher incidence of cardiovascular adverse events. However, the mechanism underlying such cardiopathogenic side effects in MM patients remains elusive. Here, we show that carfilzomib-specific proteasome inhibition profoundly impairs cardiomyocyte contractility.

View Article and Find Full Text PDF